rewirebio.iobenchmarks
Evidence and investigation

Contested results

Where one study disagrees with what other studies report for the same models, and what we are doing to resolve each case.

These are automatic leads, not findings of error. Each release, a check compares how every study ranks the models it shares with other studies. It flags a study that reverses the order the others agree on, or whose gap to a shared reference model lies well outside theirs. Different tasks, populations or metrics often explain a flag.

A flag never hides a result. Flagged results stay in every table, page and download, marked Contested. A result is withheld only when a reviewer marks it disputed.

How the check works, and how each follow-up is recorded: discrepancies between studies.

In this release

  • 121open
  • 5settled
  • 7resolved
  • 1medium severity
  • 132low severity

Release 2026-11-02-a7f03c9e55a5 · 133 findings in all · rules version 4

Findings

Status: All · Open · Settled · Resolved

Severity: All · Medium · Low

State: All · Not yet reviewed · Under investigation · Explained · Confirmed error · Not a real disagreement

Showing findings that compare MutPred. All models

2 findings match, most severe first.

MutPred and ESM-1b: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) reverses the order

  • Low severity
  • Not yet reviewed
  • Ordering reversal
  • Same task, different protocols

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks ESM-1b above MutPred in 6 of 7 comparisons; 2 of 2 other studies rank MutPred above ESM-1b.

3 papers rank MutPred above ESM-1b in 8 of their 11 comparisons and ESM-1b higher in 1; 2 are ties. Of those papers, ProteinGym ranks ESM-1b higher on its own (1 of 1). Livesey and Marsh 2025 ranks ESM-1b above MutPred in 6 of its 7 comparisons and MutPred higher in 1.

Comparisons in which each paper scores MutPred or ESM-1b higher3 other papers: MutPred higher in 8, ESM-1b higher in 1, 2 ties. Livesey and Marsh 2025 (disagrees): MutPred higher in 1, ESM-1b higher in 6, 0 ties.3 other papers8 MutPred higher82 tie21 ESM-1b higher1Disagrees: Livesey and Marsh 2025Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)1 MutPred higher16 ESM-1b higher6
MutPred higherTieESM-1b higher
Compared
MutPred, ESM-1b

Not reviewed yet.

MutFormer and MutPred: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • two-study-conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above MutPred in 6 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MutPred above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above MutPred in 6 of their 13 comparisons and MutPred higher in 7. Of those papers, An openly licensed benchmark… ranks MutPred higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or MutPred higher2 other papers: MutFormer higher in 6, MutPred higher in 7, 0 ties.2 other papers6 MutFormer higher67 MutPred higher7
MutFormer higherTieMutPred higher
Compared
MutFormer, MutPred

Not reviewed yet.